Quality Measure and Weight Loss Assessment in Patients with Type 2 Diabetes Mellitus Treated with Canagliflozin or Dipeptidyl Peptidase-4 Inhibitors

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2017 Jun 10

PMID 28595617

Authors

Carol H Wysham

Patrick Lefebvre

Dominic Pilon

Mike Ingham

Marie-Helene Lafeuille

Bruno Emond

Rhiannon Kamstra

Wing Chow

Michael Pfeifer

Mei Sheng Duh

Affiliations

Soon will be listed here.

Abstract

Background: Achieving control of glycated hemoglobin (HbA1c), blood pressure (BP), and body weight (BW) remains a challenge for most patients with type 2 diabetes mellitus (T2DM). In clinical trials, canagliflozin (CANA), an inhibitor of sodium-glucose co-transporter 2, has shown significant improvement compared to some dipeptidyl peptidase-4 (DPP-4) inhibitors in the achievement of such quality measures. This study used recent electronic medical records (EMR) data to assess quality measure achievement of HbA1C, BP, and BW loss in patients treated with CANA versus DPP-4 inhibitors.

Methods: Adult patients with ≥1 T2DM diagnosis and ≥12 months of clinical activity (baseline) before first CANA or DPP-4 prescription (index) were identified in the QuintilesIMS Health Real-World Data EMRs-US database (03/29/2012-10/30/2015). Patients were observed from the index to last encounter. Inverse probability of treatment weighting (IPTW) was used to adjust for observed baseline confounders between groups. Kaplan-Meier (KM) rates and Cox proportional hazard models were used to compare achievement of HbA1c < 7% (among patients <65 years old), HbA1c < 8%, systolic BP < 140 mmHg, diastolic BP < 90 mmHg, and BW loss ≥ 5% among patients not meeting these respective targets at baseline.

Results: A total of 10,702 CANA and 17,679 DPP-4 patients were selected. IPTW resulted in balanced baseline demographic, comorbidity, and disease characteristics (CANA: N = 13,793, mean age: 59.0 years; DPP-4: N = 14,588, mean age: 58.9 years). Up until 24 months post-index, CANA patients were more likely to reach an HbA1c < 7% (hazard ratio [HR] = 1.10, P = 0.007, KM rates: 42.8% vs. 40.3%), an HbA1c < 8% (HR = 1.16, P < 0.001, KM rates: 63.7% vs. 60.0%), and a BW loss ≥ 5% (HR = 1.46, P < 0.001, KM rates: 55.2% vs. 46.2%), compared to DPP-4 patients. Up until 12 months post-index, CANA patients were more likely to reach a systolic BP < 140 mmHg (HR = 1.07, P = 0.04, KM rates: 87.8% vs. 83.9%). but not a diastolic BP < 90 mmHg (HR = 0.95, P = 0.361), compared to DPP-4 patients.

Conclusions: This retrospective study of EMR data covering up to 30 months after CANA approval (March 2013) suggests that patients initiated on CANA were more likely to reach HbA1c, systolic BP, and weight loss objectives specified by general diabetes care guidelines than patients initiated on DPP-4 inhibitors.

References

Phung O, Scholle J, Talwar M, Coleman C . Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303(14):1410-8. DOI: 10.1001/jama.2010.405. View

Stenlof K, Cefalu W, Kim K, Alba M, Usiskin K, Tong C . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4):372-82. PMC: 3593184. DOI: 10.1111/dom.12054. View

Palmer A, Roze S, Valentine W, Minshall M, Hayes C, Oglesby A . Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin. 2004; 20 Suppl 1:S53-8. DOI: 10.1185/030079903125002611. View

Grabner M, Peng X, Geremakis C, Bae J . Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. J Manag Care Spec Pharm. 2015; 21(12):1204-12. PMC: 10398281. DOI: 10.18553/jmcp.2015.21.12.1204. View

Stolar M . Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010; 123(3 Suppl):S3-11. DOI: 10.1016/j.amjmed.2009.12.004. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

Cefalu W, Leiter L, Yoon K, Arias P, Niskanen L, Xie J . Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896):941-50. DOI: 10.1016/S0140-6736(13)60683-2. View

Fulcher G, Matthews D, Perkovic V, de Zeeuw D, Mahaffey K, Mathieu C . Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 18(1):82-91. DOI: 10.1111/dom.12589. View

Seufert J . SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015; 8:543-54. PMC: 4644173. DOI: 10.2147/DMSO.S90662. View

10.

Handelsman Y, Bloomgarden Z, Grunberger G, Umpierrez G, Zimmerman R, Bailey T . American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015; 21 Suppl 1:1-87. PMC: 4959114. DOI: 10.4158/EP15672.GL. View

11.

Battise D . Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes. Clin Diabetes. 2015; 32(2):81-6. PMC: 4485248. DOI: 10.2337/diaclin.32.2.81. View

12.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

13.

Austin P, Stuart E . The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2015; 26(4):1654-1670. PMC: 5564952. DOI: 10.1177/0962280215584401. View

14.

Lavalle-Gonzalez F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W . Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12):2582-92. PMC: 3825495. DOI: 10.1007/s00125-013-3039-1. View

15.

Schernthaner G, Gross J, Rosenstock J, Guarisco M, Fu M, Yee J . Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36(9):2508-15. PMC: 3747923. DOI: 10.2337/dc12-2491. View

16.

Bailey R, Vijapurkar U, Meininger G, Rupnow M, Blonde L . Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. Clin Ther. 2015; 37(5):1045-54. DOI: 10.1016/j.clinthera.2015.02.020. View

17.

Grant R, Kirkman M . Trends in the evidence level for the American Diabetes Association's "Standards of Medical Care in Diabetes" from 2005 to 2014. Diabetes Care. 2014; 38(1):6-8. DOI: 10.2337/dc14-2142. View

18.

Zhang X, Zhao Q . Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. J Hypertens. 2015; 34(2):167-75. DOI: 10.1097/HJH.0000000000000782. View

19.

Hernan M, Hernandez-Diaz S, Robins J . A structural approach to selection bias. Epidemiology. 2004; 15(5):615-25. DOI: 10.1097/01.ede.0000135174.63482.43. View

20.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View